Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeo Ohba

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Pathology International|June 21, 2019
An epilepsy-associated glioneuronal tumor with mixed morphology harboring FGFR1 mutationSeiji Yamada, Sumihito Nobusawa, Tatsuya Yamazaki, et al.
Clinical Neurology and Neurosurgery|March 11, 2020
Steroid-responsive recurrent tumefactive demyelination with multiple petechial hemorrhages along non-displaced medullary veinsTakashi Tsuboi, Yumiko Harada, Masashi Suzuki, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|July 13, 2021
Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six casesSeiji Yamada, Jun Muto, Sachiko Iba, et al.
Neurosurgery|December 14, 2019
The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in GliomasShigeo Ohba, Kazuhiro Murayama, Kiyonori Kuwahara, et al.
Pathology International|April 9, 2026
Genomic Alteration Patterns Across Histological Grades in BRAF p.V600E-Mutant Gliomas and Glioneuronal Tumors: An Analysis of 15 CasesSeiji Yamada, Tetsuya Takimoto, Mina Ikeda, et al.
Scientific Reports|January 11, 2025
Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapyShigeo Ohba, Takao Teranishi, Kazuyasu Matsumura, et al.
Cancer Research|November 5, 2016
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation ProcessShigeo Ohba, Joydeep Mukherjee, Tor-Christian Johannessen, et al.
Brain Tumor Pathology|September 22, 2025
Ataxin-2 as a candidate blood biomarker for estimating disease status in cases of suspected glioblastoma recurrenceFarida Garaeva, Riho Nakajima, Sho Tamai, et al.
Neuro-Oncology Advances|December 31, 2025
Relation between tumor treating fields usage rate ≥75% for the first 3 months and progression-free survival in patients with newly diagnosed WHO grade 4 gliomasShoichi Deguchi, Masashi Kinoshita, Fumiharu Ohka, et al.
International Journal of Clinical Oncology|November 11, 2024
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resectionMasayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Pathology International|June 21, 2019
An epilepsy-associated glioneuronal tumor with mixed morphology harboring FGFR1 mutationSeiji Yamada, Sumihito Nobusawa, Tatsuya Yamazaki, et al.
Clinical Neurology and Neurosurgery|March 11, 2020
Steroid-responsive recurrent tumefactive demyelination with multiple petechial hemorrhages along non-displaced medullary veinsTakashi Tsuboi, Yumiko Harada, Masashi Suzuki, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|July 13, 2021
Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six casesSeiji Yamada, Jun Muto, Sachiko Iba, et al.
Neurosurgery|December 14, 2019
The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in GliomasShigeo Ohba, Kazuhiro Murayama, Kiyonori Kuwahara, et al.
Pathology International|April 9, 2026
Genomic Alteration Patterns Across Histological Grades in BRAF p.V600E-Mutant Gliomas and Glioneuronal Tumors: An Analysis of 15 CasesSeiji Yamada, Tetsuya Takimoto, Mina Ikeda, et al.
Scientific Reports|January 11, 2025
Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapyShigeo Ohba, Takao Teranishi, Kazuyasu Matsumura, et al.
Cancer Research|November 5, 2016
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation ProcessShigeo Ohba, Joydeep Mukherjee, Tor-Christian Johannessen, et al.
Brain Tumor Pathology|September 22, 2025
Ataxin-2 as a candidate blood biomarker for estimating disease status in cases of suspected glioblastoma recurrenceFarida Garaeva, Riho Nakajima, Sho Tamai, et al.
Neuro-Oncology Advances|December 31, 2025
Relation between tumor treating fields usage rate ≥75% for the first 3 months and progression-free survival in patients with newly diagnosed WHO grade 4 gliomasShoichi Deguchi, Masashi Kinoshita, Fumiharu Ohka, et al.
International Journal of Clinical Oncology|November 11, 2024
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resectionMasayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, et al.
Pageof 10